We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Blood Test Could Predict Relapse of Autoimmune Blood Vessel Disease

By LabMedica International staff writers
Posted on 25 Apr 2025

Neutrophils, once believed to be uniform in nature, have been discovered to exhibit significant diversity. More...

These immune cells, which play a crucial role in fighting infections, are also implicated in autoimmune diseases. Now, new research has revealed that a specific subset of neutrophils can predict disease relapse early, potentially paving the way for more tailored treatment approaches.

A study published in Nature Communications and led by a multi-institutional research team from The University of Osaka (Osaka, Japan) explored the dominant cell types in the blood of patients at the early stages of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. This disease, caused by inflammation in the blood vessels, can lead to organ dysfunction. The research team enrolled six patients and seven healthy controls for comparison, collecting around 180,000 white blood cells. These cells were subjected to single-cell analysis to examine their genetic characteristics and surface proteins. The analysis of the transcriptome and proteome revealed a significantly higher proportion of two specific neutrophil subpopulations in the patients compared to healthy individuals. Notably, the researchers found an increase in a highly activatable subset of neutrophils in the patients. These cells were found to be responsive to interferon-gamma (IFN-g), a key protein involved in inflammation.

Among the patients, those showing the highest expression of IFN-g response genes were found to have persistent vasculitis symptoms even after treatment, suggesting that this particular neutrophil subpopulation plays a role in the persistent nature of vasculitis. To further investigate, the team analyzed the levels of IFN-g in stored serum samples from 37 patients, some of whom were newly diagnosed and others who had undergone treatment. The results were striking. Of the 24 new-onset patients assessed, the six with the highest serum IFN-g concentrations all experienced relapses, suggesting that measuring IFN-g levels could serve as an early indicator of disease relapse. This research offers a deeper understanding of the immune mechanisms underlying ANCA-associated vasculitis and suggests potential new strategies for disease monitoring and treatment. By identifying specific neutrophil populations involved in disease progression, these findings could lead to more personalized therapies, ultimately improving outcomes for patients suffering from this rare but serious condition.

Related Links:
University of Osaka 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Hematology Consumables
Bioblood Devices
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.